Dual Chamber Prefilled Syringes Market Set to Deliver Major Revenue Shares durin

Posted by Arslan on January 24th, 2019

Dual chamber prefilled syringes are being widely utilized for storing biological substances or active pharmaceutical components that cannot be stable for extended duration.

A CAGR of 8.7% has been projected for the global dual chamber prefilled syringes market during the forecast period, 2017 to 2026, according to a new study of Fact.MR. Roughly US$ 3,300 Mn worth of dual chamber prefilled syringes are likely to be sold across the globe by 2026-end.

Key players actively underpinning the market growth, as profiled by Fact.MR’s report, include Pfizer Inc., Amgen Inc., Boehringer Ingelheim GmbH, Nipro Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, Gerresheimer AG, Ypsomed Holding AG, West Pharmaceutical Services, Inc., Schott AG, Otsuka America Pharmaceutical, Inc., Credence MedSystems, Inc., Catalent, Inc., and Bespak Europe Ltd.

In order to offer readers with up-to-date information about the latest advancements in the global dual chamber prefilled syringes market, the report provides updates about market opportunities, which can benefit leading manufacturers of dual chamber prefilled syringes. With continuous evolution of the healthcare sector, keeping a record of latest developments and trends is fundamental for dual chamber prefilled syringes manufacturers to formulate key business strategies. Detailed insights about raw material sourcing, supply chain, regulatory approvals, pricing analysis, list of distributors, and cost structure are provided in this section. The Fact.MR report provides segment-wise analysis and forecast for covering the wide scope of global dual chamber prefilled syringes market. The global market for dual chamber prefilled syringes has been segmented into sales channel, product type, product material, and region. In this segmentation. 

North America to Remain Most Remunerative for Dual Chamber Prefilled Syringes Market

North America will continue to be the most remunerative market for dual chamber prefilled syringes. Dominance of North America in the market can be highly attributed to growing prevalence of chronic diseases in the region coupled with high penetration of biologics and biosimilars. Geographical expansion of North America-based market players, high demand for self-injection devices and growing geriatric population are some other factors driving growth of the market in North America.

Glass to Remain Preferred Product Material for Dual Chamber Prefilled Syringes

Glass will remain preferred product material for dual chamber prefilled syringes, mainly because of its non-reactive nature, and properties such as chemical and heat resistance. However sales of glass prefilled syringes will witness a comparatively slower expansion than plastic prefilled syringes through 2026. 

Lyophilized drugs have represented a robust penetration worldwide in the recent past. Lyophilized drugs account for largest share of all reconstitution-requiring injectable/infusible drugs. As a large number of injectable/infusible drugs have been developed for self-administration, special challenges are incurred for the drug developers. However, dual chamber prefilled syringes, which are particularly designed for simplifying reconstitution devoid of patient handling of diluent or drug, have become the mainstay option for delivering these drugs, meanwhile curtailing challenges faced by developers.